Krysta Loveland, DPM
Foot & Ankle Surgery · Lansing, MINPI 1346773157
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,527 of the $29,951 with a category attached, or 61.9%. Kerecis Limited accounts for 73.8% of it on its own, with 26 other manufacturers making up the rest. 2025 is the largest year on record at $14,435, more than ten times the $1,422 reported in 2020. Among foot & ankle surgery clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 184 payments — averaging $162.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kerecis Limited$22K
- Treace Medical Concepts, Inc.$2K
- Stryker$2K
- Paragon 28, Inc.$1K
- Smith+Nephew$840
- Osteomed LLC$599
- plus $2K from 21 others
What the payments were for
- Speaking & faculty fees$18,52762%
- Travel & lodging$3,32011%
- Food & beverage$7,63325%
- Education$4712%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kerecis Limited | 25 | $22,089 |
| Treace Medical Concepts, Inc. | 21 | $1,990 |
| Stryker(2 entities) | 27 | $1,525 |
| Paragon 28, Inc. | 18 | $1,240 |
| Smith+Nephew | 40 | $840 |
| Osteomed LLC | 11 | $599 |
| Bioventus LLC | 6 | $305 |
| Tactile Systems Technology Inc | 6 | $146 |
| Boston Scientific | 1 | $138 |
| Amgen(2 entities) | 6 | $130 |
| Zak Ortho | 1 | $125 |
| Acumed LLC | 1 | $125 |
| Johnson & Johnson | 2 | $117 |
| Medline Industries LP | 1 | $97 |
| Cardiovascular Systems Inc. | 2 | $94 |
| Urgo Medical North America, LLC | 2 | $93 |
| AbbVie | 3 | $70 |
| Organogenesis Inc. | 2 | $45 |
| Acera Surgical, Inc. | 1 | $30 |
| Averitas Pharma Inc. | 1 | $25 |
| Penumbra, Inc. | 1 | $23 |
| Heron Therapeutics, Inc. | 1 | $21 |
| Mimedx Group, Inc. | 1 | $18 |
| Solventum Corporation | 1 | $18 |
| KCI USA, Inc. | 1 | $17 |
| Integra Lifesciences Corporation | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerecis SurgiClose$46,068
- Kerecis Omega3 Marigen$40,681
- Kerecis GraftGuide$11,517
- Kerecis Omega3 SurgiClose$10,252
- LAPIPLASTY SYSTEM 1$888
- Kerecis Omega3 GraftGuide$327
- Lapiplasty System$266
- TMC NANOPLASTY SYSTEM$249
- ACUMED$249
- Product Portfolio$186
- FLEXBAND$174
- HOFFMANN$173
- Actishield$136
- AUGMENT INJECTABLE$130
- OsteoMed$125
- Exogen Ultrasound Bone Healing System$117
- TMC SPEEDMTP$113
- EXT-Extremilock Foot$112
- PROstep$108
- EXT-ExtremiLock Ankle$106
How this compares
$29,951 in reported general payments places this provider in the 95th percentile of 384 foot & ankle surgery providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 18 | $10,785 |
| Doxycycline Hyclate | 60 | $341 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 27 | $294 |
| Ciclopirox | 16 | $292 |
| Levofloxacin | 26 | $138 |
| Methylprednisolone | 13 | $75 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $42 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $840 | $10,78518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 384 foot & ankle surgery providers in Michigan.
Other foot & ankle surgery in Lansing
- Michael SwordsLansing$189K
- John AndersonGrand Rapids$1.3M
- Brian LoderClinton Township$854K
- Karl DunnClinton Twp$434K
- Anthony LalamaMacomb$421K
- Christopher ZingasSaint Clair Shores$227K
- John MaskillGrand Rapids$202K
- Gregory SheremetaTroy$87K
- Jason WesloskyClinton Township$87K
- Hatim BurhaniGrosse Pointe Woods$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.